Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer

BACKGROUND: Preoperative radiochemotherapy (RCT) with 5-FU or capecitabine is the standard of care for patients with locally advanced rectal cancer (LARC). Preoperative RCT achieves pathological complete response rates (pCR) of 10-15%. We conducted a single arm phase II study to investigate the feas...

Descripción completa

Detalles Bibliográficos
Autores principales: Dellas, Kathrin, Höhler, Thomas, Reese, Thomas, Würschmidt, Florian, Engel, Erik, Rödel, Claus, Wagner, Wolfgang, Richter, Michael, Arnold, Dirk, Dunst, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3679876/
https://www.ncbi.nlm.nih.gov/pubmed/23587311
http://dx.doi.org/10.1186/1748-717X-8-90

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3679876/
https://www.ncbi.nlm.nih.gov/pubmed/23587311
http://dx.doi.org/10.1186/1748-717X-8-90

Ejemplares similares